FDA's Global Reliance Disclosure Program: what minimally redacted approval packages mean for filings
FDA will share less-redacted approval packages with applicants for use abroad, starting with PEPFAR tentative approvals and widening to novel drugs and biologics in January 2027.
What happened
On 17 November 2026 FDA launched the Global Reliance Disclosure Program. Under it, applicants can obtain minimally redacted FDA approval packages to support filings with foreign regulators. The first phase covers PEPFAR tentative approvals. In January 2027 the scheme widens to novel drugs and biologics.
FDA frames the programme as a way to expand patient access to medicines worldwide. The published record does not say how applicants request a package, what the timelines are, whether fees apply, or which foreign authorities have agreed to accept the material. Those details are not yet known and will determine how useful the programme is in practice.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA launches Global Reliance Disclosure Program to share approval packages for foreign regulators' use FDA · Tue 17 Nov 2026
- FDA approves Novartis' Cosentyx 150 mg for polymyalgia rheumatica Novartis Pharma AG · Tue 17 Nov 2026
- FDA approves Lembaz, first drug shown to extend survival in infantile-onset Niemann-Pick type C FDA · Tue 17 Nov 2026
- Infarmed allows English-labelled Teva UK dapagliflozin to ease Dalzior 10 mg supply shortage in Portugal INFARMED · Tue 17 Nov 2026
- EMA group publishes amended EU influenza vaccine composition recommendations for 2026/2027 season EMA · Tue 17 Nov 2026
- EMA extends 2026/2027 flu vaccine composition advice to mRNA influenza vaccines EMA · Tue 17 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.